Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Endocrine 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 8Mycophenolic Acid 8Cyclosporine 8Cyclophosphamide 7Tacrolimus 5Filgrastim 5Cytarabine 5Carboplatin 4Azacitidine 4olaparib 3Thiotepa 3Lenalidomide 3Etoposide 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3venetoclax 2tipifarnib 2sargramostim 2peginesatide 2laromustine 2hematide 2enasidenib 2alvocidib 2aldesleukin 2Vorinostat 2Tretinoin 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Iodine-131 × Classical hematology × Clear all
NCT00589316 2023-02-09

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1 Terminated
26 enrolled 21 charts
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡